Du Yabing, Han Yikai, Wang Xin, Wang Huanrong, Qu Yanhong, Guo Kaiyuan, Ma Wang, Fu Lijun
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Department of Radiotherapy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Front Oncol. 2022 Mar 21;12:772723. doi: 10.3389/fonc.2022.772723. eCollection 2022.
Chemotherapy resistance in breast cancer is an important factor affecting the prognosis of breast cancer patients. We computationally analyzed the differences in gene expression before and after chemotherapy in breast cancer patients, drug-sensitive groups, and drug-resistant groups. Through functional enrichment analysis, immune microenvironment analysis, and other computational analysis methods, we identified PRC1, GGTLC1, and IRS1 as genes that may mediate breast cancer chemoresistance through the immune pathway. After validation of certain other clinical datasets and cellular assays, we found that the above three genes influenced drug resistance in breast cancer patients and were closely related to the tumor immune microenvironment. Our finding that chemoresistance in breast cancer could be influenced by the mediation of tumor immunity expanded our knowledge of how to address this problem and could guide future research involving chemoresistance.
乳腺癌中的化疗耐药是影响乳腺癌患者预后的重要因素。我们通过计算分析了乳腺癌患者、药物敏感组和耐药组化疗前后的基因表达差异。通过功能富集分析、免疫微环境分析等计算分析方法，我们确定PRC1、GGTLC1和IRS1为可能通过免疫途径介导乳腺癌化疗耐药的基因。在对其他一些临床数据集和细胞试验进行验证后，我们发现上述三个基因影响乳腺癌患者的耐药性，并且与肿瘤免疫微环境密切相关。我们发现乳腺癌的化疗耐药可能受肿瘤免疫介导的影响，这扩展了我们对如何解决这一问题的认识，并可为未来涉及化疗耐药的研究提供指导。
